Miner Company
AI Revolutionizing Biopharma: Faster, Better, Cheaper
AI is poised to transform biopharma by reducing drug development time, cost, and risk, recalibrating the industry's core valuation drivers. AI-enabled assets show a dramatic improvement in risk-adjusted net present value, with my modeled example shifting from negative $238.5M to positive $356.5M.
AI is poised to transform biopharma by reducing drug development time, cost, and risk, recalibrating the industry's core valuation drivers. AI-enabled assets show a dramatic improvement in risk-adjusted net present value, with my modeled example shifting from negative $238.5M to positive $356.5M.